The BK: KIDNI Trial (BK: Kinase Inhibition to Decrease Nephropathy Intervention Trial)

This is a randomized controlled trial to determine whether specific therapy aimed at reducing viral damage to the transplant kidney will have a better outcome than standard therapy, which currently consists of reducing immunosuppression. Infection with the BK virus in kidney transplants can lead to transplant failure. We have chosen this therapy with two immunosuppressive medications based upon the biology of the BK virus. This virus hijacks the cellular machinery to reproduce itself, and in passing activates inflammation and scarring. Our therapy will interrupt this process, and result in less scarring and will maintain renal transplant function.